2022
Randomized Clinical Trials of Machine Learning Interventions in Health Care
Plana D, Shung DL, Grimshaw AA, Saraf A, Sung JJY, Kann BH. Randomized Clinical Trials of Machine Learning Interventions in Health Care. JAMA Network Open 2022, 5: e2233946. PMID: 36173632, PMCID: PMC9523495, DOI: 10.1001/jamanetworkopen.2022.33946.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsRisk of biasClinical trialsSystematic reviewNon-RCT designHealth careCONSORT-AIClinical adoptionCochrane riskOvid EmbaseCochrane LibraryTrial characteristicsOvid MEDLINEPrimary interventionExclusion criteriaCommon reasonMedian proportionPatient careRCT designLiterature searchOverall riskRelevant articlesLack of participantsTrialsGoogle Scholar
2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology 2020, 6: 1759-1765. PMID: 32970151, PMCID: PMC7516804, DOI: 10.1001/jamaoncol.2020.4338.Peer-Reviewed Original ResearchConceptsProgression-free survivalHigh-risk MMBackbone regimensRefractory MMHazard ratioMultiple myelomaClinical trialsSystematic reviewDerSimonian-Laird random-effects modelPhase 3 trialImproved response ratesPreferred Reporting ItemsRandom-effects modelCochrane riskSame regimenCytogenetic riskCochrane LibraryMeeting libraryI2 statisticImproved outcomesMAIN OUTCOMEThird investigatorCochran's QPatientsReporting Items